Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Monolaurin, a monoglyceride derived from lauric acid found in coconut oil and breast milk, has been studied for its antimicrobial properties, including activity against Staphylococcus aureus (Staph). Laboratory (in vitro) studies have demonstrated that monolaurin can disrupt the lipid membranes of certain bacteria, including both methicillin-sensitive and methicillin-resistant S. aureus (MRSA). For example, research published in Antimicrobial Agents and Chemotherapy (1992) and more recent studies (e.g., Journal of Medicinal Food, 2013) have shown that monolaurin inhibits the growth of Staph bacteria in petri dishes. The proposed mechanism involves the breakdown of the bacterial cell membrane, leading to cell death.

However, while these laboratory findings are promising, clinical trials in humans are lacking. There is currently no strong evidence from randomized, controlled human studies showing that oral or topical monolaurin effectively treats or prevents Staph infections. Most of the evidence supporting its use is preclinical, and its safety and efficacy in real-world infections remain unproven. As such, while there is a scientific rationale and laboratory evidence supporting monolaurin’s antibacterial effects, more research—especially in humans—is needed before it can be recommended as a treatment for Staph infections. It should not be used as a substitute for proven medical therapies, especially in serious or systemic infections.

More about monolaurin
More about Staph Infections

Other ingredients used for Staph Infections

Other health conditions supported by monolaurin

Products containing monolaurin